MHCquant2 refines immunopeptidomics tumor antigen discovery
Authors:
- Jonas ScheidJSJonas Scheid
- Steffen LemkeSLSteffen Lemke
- Naomi Hoenisch-GravelNHNaomi Hoenisch-Gravel
- Timo SachsenbergTSTimo Sachsenberg
- Arthur DeclerqADArthur Declerq
- Ralf GabrielsRGRalf Gabriels
- Jens BauerJBJens Bauer
- Marcel WackerMWMarcel Wacker
- Leon BichmannLBLeon Bichmann
- Lennart MartensLMLennart Martens
- Marissa L. DubbelaarMDMarissa L. Dubbelaar
Preprint
- 4 December 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
The identification of human leukocyte antigen (HLA)-presented peptides as targets of anti-cancer T cell response is pivotal for the development of novel immunotherapies. Mass spectrometry (MS)-based immunopeptidomics enables the detection of these peptides, yet confident identifications and thus implementation in immunotherapy design are hampered by the high diversity and low abundance of naturally presented HLA peptides. Here, we introduce MHCquant2, a Nextflow-based open-source pipeline that leverages OpenMS tools and peptide property predictors (DeepLC, MS2PIP) for highly sensitive and scalable HLA peptide identification and quantification across various MS platforms. MHCquant2 increased peptide identifications up to 27% with a significant expansion of low-abundant peptides, outperforming state-of-the-art pipelines. Using MHCquant2 we build a comprehensive benign tissue repository comprising re-analyzed data from available benign immunopeptidomes and a novel benignMHCquant2 dataset, adding more than 160,000 novel naturally presented HLA peptides. First applications of this benign repository and the MHCquant2 pipeline enabled (i) the refinement of tumor-associated antigens, (ii) the detection of novel, high-frequent tumor-exclusive peptide antigens for multiple tumor entities, and (iii) the identification and quantification of mutation-derived low-abundant neoepitopes. MHCquant2 refines tumor antigen discovery in immunopeptidomics, paving the way for the implementation of off-the-shelf and personalized immunotherapy design.Keywords
All Related Versions
Funding Information
- Deutsche Forschungsgemeinschaft (EXC2180-390900677)
- Deutschen Konsortium für Translationale Krebsforschung (70114948)
- Else Kröner-Fresenius-Stiftung (2022_EKSE.79)
- Fonds Wetenschappelijk Onderzoek (12B7123N, G010023N, G028821N, 1SE3724N)
- CHIST-ERA (ODEEP-EU)
This publication has 59 references indexed in Scilit:
- MS2Rescore: Data-Driven Rescoring Dramatically Boosts Immunopeptide Identification RatesMolecular & Cellular Proteomics, 2022
- MhcVizPipe: A Quality Control Software for Rapid Assessment of Small- to Large-Scale Immunopeptidome DatasetsMolecular & Cellular Proteomics, 2021
- Trapped Ion Mobility Spectrometry and Parallel Accumulation–Serial Fragmentation in ProteomicsMolecular & Cellular Proteomics, 2021
- Extending Comet for Global Amino Acid Variant and Post‐Translational Modification Analysis Using the PSI Extended FASTA FormatProteomics, 2020
- In Immunopeptidomics We Need a Sniper Instead of a ShotgunProteomics, 2018
- Fast and Accurate Protein False Discovery Rates on Large-Scale Proteomics Data Sets with Percolator 3.0Journal of the American Society for Mass Spectrometry, 2016
- Getting intimate with trypsin, the leading protease in proteomicsMass Spectrometry Reviews, 2013
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992
- Dissection of human allostimulatory determinants with cloned T cells: Stimulation inhibition by monoclonal antibodies TÜ22, 34, 36, 37, 39, 43, and 58 against distinct human MHC class II moleculesHuman Immunology, 1985
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978